Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Benzyl alcohol is scientifically validated as a treatment for scabies, specifically as a topical prescription medication. The U.S. Food and Drug Administration (FDA) approved a 5% benzyl alcohol lotion (commercially known as Ulesfia) for the treatment of head lice and it has been investigated for use in scabies, particularly in patients where first-line treatments such as permethrin or ivermectin are unsuitable or ineffective. The mechanism of action is thought to involve asphyxiation of the mites by obstructing their spiracles (respiratory openings), rather than neurotoxicity, which is the basis for other common scabicides.

Several clinical studies have evaluated the efficacy of benzyl alcohol for scabies. For example, a 2009 randomized controlled trial published in the journal Dermatology found that a 10% benzyl alcohol lotion was effective in reducing mite counts and symptoms in patients with scabies, though it was generally less effective than permethrin. The use of benzyl alcohol is generally reserved for cases where other treatments cannot be used, particularly in infants or pregnant women, due to its relatively favorable safety profile.

Despite scientific support, benzyl alcohol is not the first-line therapy but is recognized as a viable alternative, especially in populations where safety is a concern. The evidence base, while positive, is not as robust or extensive as that for permethrin or ivermectin, hence a moderate evidence rating.

More about benzyl alcohol
More about Scabies

Other ingredients used for Scabies

Other health conditions supported by benzyl alcohol

Products containing benzyl alcohol